227 related articles for article (PubMed ID: 33502319)
1. Efficacy of Mepolizumab Extended Interval Dosing for 2 Asthmatic Patients With Chronic Eosinophilic Pneumonia.
Sato H; Miyata Y; Inoue H; Tanaka A; Sagara H
J Investig Allergol Clin Immunol; 2021 Oct; 31(5):459-460. PubMed ID: 33502319
[No Abstract] [Full Text] [Related]
2. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia.
Shimizu Y; Kurosawa M; Sutoh Y; Sutoh E
J Investig Allergol Clin Immunol; 2020 Apr; 30(2):154-155. PubMed ID: 31778113
[No Abstract] [Full Text] [Related]
4. Secondary loss of response to mepolizumab in severe eosinophilic asthma.
Cormier M; Chaboillez S; Lemiere C
J Allergy Clin Immunol Pract; 2020 Feb; 8(2):736-738. PubMed ID: 31421278
[No Abstract] [Full Text] [Related]
5. Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma.
Howarth P; Quirce S; Papi A; Israel E; Mallett S; Bates S; Yancey S; Albers FC; Kwon N
Allergy; 2020 Aug; 75(8):2085-2088. PubMed ID: 32147844
[No Abstract] [Full Text] [Related]
6. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.
Weir E; Paton J
J Asthma; 2020 May; 57(5):521-524. PubMed ID: 30795693
[No Abstract] [Full Text] [Related]
7. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
Comberiati P; McCormack K; Malka-Rais J; Spahn JD
J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
[TBL] [Abstract][Full Text] [Related]
8. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
Kurosawa M; Sutoh E
Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
[No Abstract] [Full Text] [Related]
9. A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting.
Cameli P; Bergantini L; d'Alessandro M; Perruzza M; Cekorja B; Perillo F; Massa E; Ruzza A; Fossi A; Beltrami V; Sestini P; Bargagli E
Int Arch Allergy Immunol; 2020; 181(8):606-612. PubMed ID: 32516771
[TBL] [Abstract][Full Text] [Related]
10. Long-term use of mepolizumab in a case of chronic eosinophilic pneumonia: extending interval dosing.
Prieto-García A; Peligros MI; Pérez Tamayo I; Zubeldia JM; Álvarez-Sala L; Lavilla C
J Asthma; 2024 Jan; 61(1):69-71. PubMed ID: 37467753
[TBL] [Abstract][Full Text] [Related]
11. Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy.
Howarth P; Chupp G; Nelsen LM; Bradford ES; Bratton DJ; Smith SG; Albers FC; Brusselle G; Bachert C
J Allergy Clin Immunol; 2020 Jun; 145(6):1713-1715. PubMed ID: 32084443
[No Abstract] [Full Text] [Related]
12. Mepolizumab for Treatment of Severe Eosinophilic Asthma: A 5-Year Real-World Experience.
Loli-Ausejo D; Perdomo G; Mascaró B; Martínez-Olondris P; Sánchez-Fernández MC; Mullol J; Valero A; Arismendi E; Bobolea I
J Investig Allergol Clin Immunol; 2023 Jun; 33(3):209-210. PubMed ID: 36820628
[No Abstract] [Full Text] [Related]
13. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies.
Albers FC; Price RG; Smith SG; Yancey SW
J Allergy Clin Immunol; 2017 Nov; 140(5):1464-1466.e4. PubMed ID: 28687231
[No Abstract] [Full Text] [Related]
14. Mepolizumab (Nucala) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2016 Jan; 58(1486):11-2. PubMed ID: 26761344
[No Abstract] [Full Text] [Related]
15. A case of chronic eosinophilic pneumonia successfully treated with mepolizumab.
To M; Kono Y; Yamawaki S; Soeda S; Katsube O; Kishi H; To Y
J Allergy Clin Immunol Pract; 2018; 6(5):1746-1748.e1. PubMed ID: 30201098
[No Abstract] [Full Text] [Related]
16. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
[TBL] [Abstract][Full Text] [Related]
17. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
Strauss RA; Jawhari N
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
[No Abstract] [Full Text] [Related]
18. Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis.
Lugogo N; Liu MC; Pavord I; Mitchell PD; Smith SG; Mallett S; Albers FC; Bradford ES; Yancey SW; Bel EH
J Allergy Clin Immunol Pract; 2021 Sep; 9(9):3506-3509.e3. PubMed ID: 34111572
[No Abstract] [Full Text] [Related]
19. Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use.
Albers FC; Hozawa S; Bratton DJ; Yancey SW; Prazma CM; Humbert M; Liu MC
Allergy; 2020 Apr; 75(4):942-946. PubMed ID: 31520471
[No Abstract] [Full Text] [Related]
20. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response.
Caminati M; Cegolon L; Vianello A; Chieco Bianchi F; Festi G; Marchi MR; Micheletto C; Mazza F; Tognella S; Senna G
Expert Rev Respir Med; 2019 Dec; 13(12):1205-1212. PubMed ID: 31592700
[No Abstract] [Full Text] [Related]
[Next] [New Search]